S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

$288.78
+3.73 (+1.31 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$283.40
Now: $288.78
$289.01
50-Day Range
$261.12
MA: $277.99
$289.89
52-Week Range
$198.74
Now: $288.78
$294.57
Volume286,787 shs
Average Volume422,814 shs
Market Capitalization$24.77 billion
P/E Ratio59.18
Dividend YieldN/A
Beta0.76
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$5.35 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Employees8,377
Market Cap$24.77 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has initiated a share buyback program on Wednesday, February 12th 2020, which permits the company to repurchase 5,000,000 shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's board believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Friday, January, 31st. The company reported $1.04 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.91 by $0.13. The company had revenue of $605.50 million for the quarter, compared to the consensus estimate of $600.60 million. IDEXX Laboratories had a return on equity of 283.27% and a net margin of 17.77%. The business's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.98 earnings per share. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided earnings per share (EPS) guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

What price target have analysts set for IDXX?

6 Wall Street analysts have issued 12-month price targets for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' stock price to reach $293.33 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:
  • 1. According to Zacks Investment Research, "IDEXX exited the fourth quarter on a strong note, with better-than-expected numbers. The solid organic revenue growth during the quarter, driven by strong sales at the CAG business, is encouraging. The company witnessed sturdy gains from CAG Diagnostics in the quarter. It also saw strong performances by IDEXX VetLab consumables, reference laboratory diagnostic and consulting as well as moderately robust growth in rapid assay product revenues globally. The strong performance can also be attributed to impressive growth in the LPD and water segments. The global adoption of its latest products and services, including the rapid expansion of Catalyst installed base, is another contributing factor. Over the past three months, IDEXX has been outperforming its industry. However, operating margin contracted during the quarter." (2/4/2020)
  • 2. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)

Has IDEXX Laboratories been receiving favorable news coverage?

News coverage about IDXX stock has trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for IDEXX Laboratories.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 6.9% from the January 15th total of 1,300,000 shares. Based on an average daily volume of 507,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.4% of the company's stock are sold short. View IDEXX Laboratories' Current Options Chain.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.40%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%), Franklin Resources Inc. (1.19%), Bank of America Corp DE (0.89%) and Bank of New York Mellon Corp (0.83%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Los Angeles Capital Management & Equity Research Inc. and First Trust Advisors LP. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Duality Advisers LP. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $288.78.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $24.77 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is http://www.idexx.com/.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  460 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  789
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Initial Coin Offering (ICO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel